Compare FDBC & SLGL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | FDBC | SLGL |
|---|---|---|
| Founded | 1902 | 1997 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 262.3M | 247.1M |
| IPO Year | 2000 | 2016 |
| Metric | FDBC | SLGL |
|---|---|---|
| Price | $46.07 | $76.70 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $110.00 |
| AVG Volume (30 Days) | 4.6K | ★ 44.6K |
| Earning Date | 01-27-2026 | 05-22-2026 |
| Dividend Yield | ★ 3.82% | N/A |
| EPS Growth | ★ 35.00 | N/A |
| EPS | ★ 4.86 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $223.84 |
| P/E Ratio | $9.27 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $37.00 | $0.42 |
| 52 Week High | $50.00 | $97.97 |
| Indicator | FDBC | SLGL |
|---|---|---|
| Relative Strength Index (RSI) | 54.33 | 50.26 |
| Support Level | $44.69 | $71.01 |
| Resistance Level | $45.67 | $95.83 |
| Average True Range (ATR) | 1.50 | 7.12 |
| MACD | 0.26 | -0.25 |
| Stochastic Oscillator | 73.07 | 58.90 |
Fidelity D & D Bancorp Inc is a bank holding company. Through its wholly-owned state-chartered commercial bank subsidiary, The Fidelity Deposit and Discount Bank (the Bank), it offers a full range of traditional banking services. The Bank has a personal and corporate trust department and also provides alternative financial and insurance products with asset management services. Its primary market areas are Lackawanna, Luzerne and Northampton Counties, Pennsylvania. The company's primary deposit products are demand deposits and interest-bearing time, money market and savings accounts. It offers a full array of loan products to meet the needs of retail and commercial customers. Company includes segments: Commercial and Industrial, Commercial Real Estate, Consumer, Residential Real Estate.
Sol-Gel Technologies Ltd is a dermatology company. It is engaged in identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases. The company's product candidate pipeline includes SGT-610 (Patidegib Gel 2%), a new chemical entity hedgehog signaling pathway blocker, for the chronic use and prevention of new BCC in Gorlin syndrome patients, and the topical drug candidate SGT-210 for the treatment of Darier Disease and other rare keratosis-related indications such as PC, PPK and Olmsted.